REL:LSERELX PLC Analysis
Data as of 2026-07-21 - not real-time
£2,468.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at 2,468 p, comfortably above the 20‑day (2,416.75 p) and 50‑day (2,443.52 p) simple moving averages and the MACD line is strongly bullish (histogram ≈ 15 p), suggesting short‑term momentum. The RSI sits at a neutral 52.7 and the price remains below the 200‑day SMA (2,742.87 p), which aligns with the system‑generated "bearish" trend flag and points to longer‑term weakness. Volume is on a decreasing trend and 30‑day volatility is elevated at 28 %, indicating a relatively choppy market environment.
Fundamentally, RELX delivers high profitability—gross margin 66 %, operating margin 31 % and profit margin 21.5 %—and generates solid free cash flow (£2.16 bn). An eye‑catching ROE of 70.5 % underscores efficient earnings generation, yet a debt‑to‑equity of 304 % and net debt of £7.27 bn raise balance‑sheet concerns. Forward earnings are priced at a PE of 15.7 versus the industry average of 30.6, and the dividend yield of 2.68 % with a 57 % payout appears sustainable. However, a DCF‑derived fair value (~£12.87) is far below the current price (~£24.68), suggesting the market may be overvalued despite the strong‑buy consensus and median target of £31.32.
Fundamentally, RELX delivers high profitability—gross margin 66 %, operating margin 31 % and profit margin 21.5 %—and generates solid free cash flow (£2.16 bn). An eye‑catching ROE of 70.5 % underscores efficient earnings generation, yet a debt‑to‑equity of 304 % and net debt of £7.27 bn raise balance‑sheet concerns. Forward earnings are priced at a PE of 15.7 versus the industry average of 30.6, and the dividend yield of 2.68 % with a 57 % payout appears sustainable. However, a DCF‑derived fair value (~£12.87) is far below the current price (~£24.68), suggesting the market may be overvalued despite the strong‑buy consensus and median target of £31.32.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above 20‑ and 50‑day SMAs
- Neutral RSI indicating room for upside
- Support level at 2,001 p providing downside cushion
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Price below 200‑day SMA signaling longer‑term weakness
- High debt‑to‑equity ratio increasing financial risk
- DCF fair value considerably lower than market price
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong profit margins and free cash flow generation
- Forward PE well below industry average indicating value
- Sustainable dividend yield of 2.68 % with solid payout ratio
Key Metrics & Analysis
Financial Health
Revenue Growth1.20%
Profit Margin21.53%
P/E Ratio22.0
ROE70.51%
ROA12.49%
Debt/Equity304.06
P/B Ratio19.0
Op. Cash Flow£2.8B
Free Cash Flow£2.2B
Industry P/E30.6
Technical Analysis
TrendBearish
RSI52.7
Support£2,001.00
Resistance£2,663.00
MA 20£2,416.75
MA 50£2,443.52
MA 200£2,742.87
MACDBullish
VolumeDecreasing
Fear & Greed Index89.82
Valuation
Fair Value£1,287.58
Target Price£3,407.50
Upside/Downside38.07%
GradeFair
TypeBlend
Dividend Yield2.68%
Risk Assessment
Beta0.20
Volatility28.08%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.